Jaguar Health Files 8-K with Exhibits

Ticker: JAGX · Form: 8-K · Filed: 2025-04-28T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, financial-statements, exhibits

Related Tickers: JAGX

TL;DR

Jaguar Health filed an 8-K on 4/28/25, mostly for financial docs & Reg FD.

AI Summary

On April 28, 2025, Jaguar Health, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Jaguar Health is providing updated financial information and disclosures to the SEC, which is standard practice for public companies.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial statements and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Jaguar Health, Inc.?

The filing is primarily for Regulation FD Disclosure and to provide Financial Statements and Exhibits.

On what date was this 8-K report filed?

The report was filed on April 28, 2025.

What is the company's principal executive office address?

The principal executive offices are located at 200 Pine Street Suite 400, San Francisco, California 94104.

What is Jaguar Health, Inc.'s telephone number?

The company's telephone number, including area code, is (415) 371-8300.

In which state was Jaguar Health, Inc. incorporated?

Jaguar Health, Inc. was incorporated in Delaware.

From the Filing

0000950170-25-058973.txt : 20250428 0000950170-25-058973.hdr.sgml : 20250428 20250428081507 ACCESSION NUMBER: 0000950170-25-058973 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250428 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250428 DATE AS OF CHANGE: 20250428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25876029 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 jagx-20250428.htm 8-K 8-K 0001585608 false 0001585608 2025-04-28 2025-04-28   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           200 Pine Street Suite 400   San Francisco , California   94104 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (415) 371-8300     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 7.01 Regulation FD Disclosure. On April 28, 2025, Jaguar Health, Inc. (the “Company”) issued a press release announcing that the Company is hosting an investor webcast on Wednesday, April 30, 2025 at 8:30 AM Eastern to review the preliminary results of the proof- of-concept investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, the Company’s plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) that were presented by Dr. Mohamad Miqdady on April 26, 2025 at the 11th Annual ELITE PED-GI Con

View on Read The Filing